“Give Me Anything But Tech”: Jim Cramer's Bold Call on the Market's Next Big Rotation

CNBC’s Jim Cramer argued the market’s last-year trade has soured as data-center capex momentum gives way to enterprise software and pharma, amid bond-market volatility and growing state-level opposition that is delaying projects in states including Texas, Pennsylvania, Virginia, and others. Software beneficiaries showed strength—ServiceNow Q2 subscription revenue rose 23% YoY (constant currency) to $3.877B and management said AI ACV exceeded expectations (> $1B), while Salesforce highlighted Agentforce ARR > $1B and combined AI+data ARR of $3.4B alongside a $25B accelerated share repurchase. Stock performance reflects the rotation (NOW +29.63% over a month, CRM +27.74%, ADBE +22.73%), but Cramer warned the rally may be driven more by buybacks than fundamentals, citing Salesforce’s retirement of 103M shares (~11%). In pharma, Johnson & Johnson reported Q2 sales of $25.3B (+5.6% operationally) and Merck/Moderna strength tied to pipeline and melanoma vaccine results also fueled the move (MRNA +115.47% past week).

Analysis

This is better viewed as a factor rotation than a clean fundamental re-rating. If permitting friction and bond volatility keep depressing hyperscaler capex, the near-term beneficiaries are the software names that monetize workflow compression and budget efficiency, but their upside is mostly multiple-driven because the underlying AI spend is still tied to the same compute stack getting constrained. That makes the trade vulnerable to margin leakage: the more these vendors lean on hyperscale partnerships, the more they inherit the same cost inflation and power scarcity they are supposed to be insulated from.

Healthcare looks more durable because it is being bought for cash flow duration, not growth optionality. JNJ is the cleaner defensive because balance-sheet support and dividend visibility matter more in a higher-rate regime; MRK has more operating torque but also more event risk, so its multiple can de-rate fast if pipeline execution slips or oncology competition tightens. MRNA is a different animal: the stock is trading like a clinical event option, which means the correct expression is likely via defined-risk structures rather than outright chase after a very large weekly move.

The contrarian risk is that this is a pause, not a regime change. If 10Y yields settle and data-center approvals clear even modestly, the market can rotate back into the AI infrastructure complex quickly, while software names face the harder question of whether AI productivity is actually monetizable enough to offset the compute bill. The clean falsifier is a re-acceleration in hyperscaler capex guidance or a sharp fall in rates; either would argue this rotation is underwritten more by macro noise than by lasting share shift.

Key Decisions for Investors

• Long JNJ / short NOW, 1:1 dollar-neutral for 1-3 months: own the lower-beta cash-return profile while fading a software name that has already rerated on a narrative trade; cover if NOW sustains post-earnings AI monetization without gross margin erosion.
• Long MRK / short ADBE for 4-8 weeks: prefer the pharma name with clearer balance-sheet and pipeline optionality over a software beneficiary that is most exposed to multiple compression if bond yields stabilize; stop if ADBE re-accelerates bookings or MRK issues pipeline updates.
• Treat MRNA as a tactical options trade only: use a small call spread or put spread around the next confirmed clinical/regulatory catalyst, not a cash equity chase after a >100% weekly move; thesis breaks if the next data readout fails to confirm durable probability-of-success.
• Watchlist alert, not a trade: if 10Y yields fall and hyperscaler capex guides up again, rotate out of software beneficiaries and back into XLK/SMH on any 3-5% pullback; that would falsify the data-center-delay thesis quickly.